Clinical Trial Update: Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cord blood transplant with Dilanubicel for HIV-positive hematologic cancers; the study was terminated and results were posted in 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Erythroid Leukemia
• Megakaryoblastic Leukemia
• Myelodysplastic Syndrome
• Myelodysplastic Syndrome with Excess Blasts
• Myelogenous Leukemia Bcr-abl1 Positive
• Non-hodgkin Lymphoma

Drugs mentioned

• Dilanubicel (dilanubicel)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2025-01-01